MajesTEC-7: A phase 3, randomized study of teclistamab + daratumumab + lenalidomide (Tec-DR) versus daratumumab + lenalidomide + dexamethasone (DRd) in patients with newly diagnosed multiple myeloma who are either ineligible or not intended for autologous stem cell transplant Meeting Abstract
| Authors: | Krishnan, A. Y.; Manier, S.; Terpos, E.; Usmani, S.; Khan, J.; Pearson, R.; Girgis, S.; Guo, Y.; McAleer, D.; Olyslager, Y.; Kampfenkel, T.; van de Donk, N. W. C. J. |
| Abstract Title: | MajesTEC-7: A phase 3, randomized study of teclistamab + daratumumab + lenalidomide (Tec-DR) versus daratumumab + lenalidomide + dexamethasone (DRd) in patients with newly diagnosed multiple myeloma who are either ineligible or not intended for autologous stem cell transplant |
| Meeting Title: | 64th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 140 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2022 Dec 10-13 |
| Meeting Location: | New Orleans, LA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2022-11-15 |
| Start Page: | 10148 |
| End Page: | 10149 |
| Language: | English |
| ACCESSION: | WOS:000893230303070 |
| DOI: | 10.1182/blood-2022-160173 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
